Small Molecules
21 December 2016
Pharnext Completes Patient Enrollment in International Pivotal Phase 3 Trial of PXT3003 for Charcot-Marie-Tooth Disease Type 1A21 December 2016
Akebia and Otsuka Pharmaceutical Announce Collaboration to Develop and Commercialize Vadadustat in the U.S.21 December 2016
ACADIA Pharmaceuticals Announces Positive Top-Line Results From Phase II Study of Pimavanserin for Alzheimer’s Disease Psychosis21 December 2016
UCB’s anti-epileptic drug VIMPAT (lacosamide) approved as monotherapy by European Commission21 December 2016
Positive Results From First Phase III Studies of Investigational Two-Drug HIV Treatment Regimen19 December 2016
Threshold Pharmaceuticals and National Cancer Institute to Collaborate on Drug Candidate TH-342419 December 2016
Tetra Discovery Partners Announces Positive Results from Phase 1 Studies of Cognition Drug Candidate, BPN1477019 December 2016
Tonix Pharmaceuticals’ PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation by the FDA19 December 2016
Sage Therapeutics Announces Initiation of Phase 2 Clinical Development for SAGE-217 in Mood Disorders19 December 2016
GSK Starts Phase III Study of Once-Daily Closed Triple Combination Therapy FF/UMEC/VI in Patients with Asthma18 December 2016
Loxo Oncology TRK Inhibitor Larotrectinib (LOXO-101) Shows Durable Anti-Tumor Activity Across TRK Fusion Cancers in ESMO Asia Phase 1 Update17 December 2016
Adamis Pharmaceuticals Announces NDA Resubmission of Its Epinephrine Pre-Filled Syringe Application to the FDA17 December 2016
New Preclinical Data Show Can-Fite’s Namodenoson (CF102) Inhibits Liver Fibrosis — Supports Potential Efficacy in Treatment of NASH17 December 2016
Novartis drug Votubia® recommended by CHMP for EU approval to treat refractory partial-onset seizures in patients with TSC17 December 2016
Actelion receives positive CHMP opinion for chlormethine gel (Ledaga) for the treatment of MF-CTCL17 December 2016
CHMP Recommends Approval of Lilly’s Baricitinib for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis (RA)16 December 2016
Agios Provides Update on PKR Program16 December 2016
RespireRx Pharmaceuticals Inc. Announces Data for CX1739 Clinical Study in Opioid Induced Respiratory Depression16 December 2016
Ironshore Pharmaceuticals Announces FDA Acceptance of HLD200 New Drug Application for Treatment of ADHD16 December 2016
Cerenis Therapeutics Receives FDA IND Approval to Begin Studies with CER-209 in NAFLD and NASH15 December 2016
Pfizer Receives FDA Approval for EUCRISA™ (crisaborole), a Novel Non-Steroidal Topical Ointment for Mild to Moderate Atopic Dermatitis (Eczema)News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports